Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines

IntroductionMultiple myeloma (MM) is a heterogeneous disease where cancer-driver mutations and aberrant signaling may lead to disease progression and drug resistance. Drug responses vary greatly, and there is an unmet need for biomarkers that can guide precision cancer medicine in this disease.Metho...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Mariaserena Giliberto, Leonardo Miranda Santana, Toril Holien, Kristine Misund, Sigve Nakken, Daniel Vodak, Eivind Hovig, Leonardo A. Meza-Zepeda, Eivind Coward, Anders Waage, Kjetil Taskén, Sigrid S. Skånland
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-11-01
coleção:	Frontiers in Oncology
Assuntos:	drug sensitivity screening multiple myeloma mutations targeted therapy MEK PI3K
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1040730/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!